Modern multiple sclerosis treatment - what is approved, what is on the horizon

Drug Discovery Today

Volumn 13, Issue 23-24, 2008, Pages 1013-1025

  Pilz, Georg ^a   Wipfler, Peter ^a   Ladurner, Gunther ^a   Kraus, Jörg ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; ROQUINIMEX; TERIFLUNOMIDE; TREOSULFAN;

ABSENCE OF SIDE EFFECTS; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EYE EDEMA; HEADACHE; HEART INFARCTION; HUMAN; HYPERSENSITIVITY REACTION; INFLAMMATION; MONOTHERAPY; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TERATOGENESIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 55749098474     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.08.003     Document Type: Review

References (108)

1. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 101 Suppl. 2 (2004) 14599-14606
2. Sobocki P., et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler. 13 (2007) 1054-1064
3. Lassmann H., and Ransohoff R.M. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol. 25 (2004) 132-137
4. McFarland H.F., and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8 (2007) 913-919
5. Holmoy T., and Hestvik A.L. Multiple sclerosis: immunopathogenesis and controversies in defining the cause. Curr. Opin. Infect. Dis. 21 (2008) 271-278
6. Noseworthy J.H., et al. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
7. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
8. Polman C.H., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
9. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
10. Jacobs L.D., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39 (1996) 285-294
11. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
12. Johnson K.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
13. Miller D.H., et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol. 39 (1996) 6-16
14. Miller D.H., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
15. Barkhof F., et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. Am. J. Roentgenol. 159 (1992) 1041-1047
16. Confavreux C., et al. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343 (2000) 1430-1438
17. Confavreux C., et al. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126 Pt 4 (2003) 770-782
18. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
19. Cutter G.R., et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 Pt 5 (1999) 871-882
20. Weiner H.L., et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J. Neuroimmunol. 104 (2000) 164-173
21. Thrower B.W. Clinically isolated syndromes: predicting and delaying multiple sclerosis. Neurology 68 24 Suppl. 4 (2007) S12-S15
22. Vollmer T., et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult. Scler. 14 (2008) 663-670
23. Rieckmann P., et al. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J. Neurol. 251 (2004) 1329-1339
24. Rieckmann P. Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006). Nervenarzt 77 (2006) 1506-1518
25. Kesselring J., and Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 4 (2005) 643-652
26. Krupp L.B., and Rizvi S.A. Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology 58 8 Suppl. 4 (2002) S32-S39
27. Henze T., et al. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur. Neurol. 56 (2006) 78-105
28. Beck R.W., et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N. Engl. J. Med. 329 (1993) 1764-1769
29. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 353 (2005) 1711-1723
30. Perumal J.S., et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur. J. Neurol. 15 (2008) 677-680
31. Keegan M., et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58 (2002) 143-146
32. Mao-Draayer Y., et al. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology 59 (2002) 1074-1077
33. Comi G., et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49 (2001) 290-297
34. Rio J., et al. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J. Neurol. 252 (2005) 795-800
35. Haas J., et al. Reduced suppressive effect of CD4+CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35 (2005) 3343-3352
36. Khan O.A., et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult. Scler. 7 (2001) 185-188
37. Kappos L., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
38. Comi G., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
39. Jacobs L.D., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343 (2000) 898-904
40. Waubant E., et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61 (2003) 184-189
41. Hemmer B., et al. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol. 4 (2005) 403-412
42. Noronha A. Neutralizing antibodies to interferon. Neurology 68 24 Suppl. 4 (2007) S16-S22
43. Ebers G., et al. The interferon beta-1b 16-year long-term follow-up study: the final results. Neurology 66 (2006) A32
44. Filippi M., et al. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol. 5 (2006) 213-220
45. Wolinsky J.S., et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61 (2007) 14-24
46. Vallittu A.M., et al. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol. Scand. 112 (2005) 234-237
47. Miller A., et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing remitting multiple sclerosis. Mult. Scler. (2008) January 21 [Epub ahead of print]
48. Ramtahal J., et al. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J. Neurol. 253 (2006) 1160-1164
49. Sorensen P.S., et al. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur. J. Neurol. 9 (2002) 557-563
50. Sorensen P.S., et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63 (2004) 2028-2033
51. Hommes O.R., et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364 (2004) 1149-1156
52. Achiron A., et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J. Neurol. 251 (2004) 1133-1137
53. Casetta I., et al. Azathioprine for multiple sclerosis. Cochrane Database Syst. Rev. 17 4 (2007) CD003982
54. Massacesi L., et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch. Neurol. 62 (2005) 1843-1847
55. La Mantia L., et al. Azathioprine. Safety profile in multiple sclerosis patients. Neurol. Sci. 28 (2007) 299-303
56. Gold R. Combination therapies in multiple sclerosis. J. Neurol. 255 Suppl. 1 (2008) 51-60
57. Tubridy N., et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53 (1999) 466-472
58. Polman C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
59. Hemmer B., et al. Central nervous system infections - a potential complication of systemic immunotherapy. Curr. Opin. Neurol. 19 (2006) 271-276
60. Bozic C., et al. Natalizumab utilization and safety in patients with relapsing multiple sclerosis: updated results from TOUCH and TYGRIS. Neurology 70 (2008) S02.002
61. Phillips J.T., et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 67 (2006) 1717-1718
62. Hauser S.L., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308 (1983) 173-180
63. Hartung H.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
64. Jeffery D.R., et al. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult. Scler. 11 (2005) 296-301
65. Neuhaus O., et al. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol. Ther. 109 (2006) 198-209
66. Boster A., et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 7 (2008) 173-183
67. Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin. Arthritis Rheum. 12 (1983) 359-372
68. Perini P., and Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J. Neurol. 250 (2003) 834-838
69. Smith D.R., et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult. Scler. 11 (2005) 573-582
70. Yang J.S., et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 156 (2004) 3-9
71. Andersen O., et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47 (1996) 895-900
72. Noseworthy J.H., et al. Linomide in relapsing and secondary progressive MS. Part I. Trial design and clinical results. Neurology 54 (2000) 1726-1733
73. Comi G., et al. The effect of two doses of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multi-center, randomized, double-blind, placebo-controlled study. Neurology 68 Suppl. 1 (2007) A84
74. Polman C., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64 (2005) 987-991
75. Romine J.S., et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians 111 (1999) 35-44
76. Brousil J.A., et al. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann. Pharmacother. 40 (2006) 1814-1821
77. Korn T., et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. 76 (2004) 950-960
78. O'Connor P.W., et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66 (2006) 894-900
79. Weissert R., et al. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J. Neuroimmunol. 144 (2003) 28-37
80. Wiendl H., et al. Treatment of active secondary progressive multiple sclerosis with treosulfan. J. Neurol. 254 (2007) 884-889
81. Sjoo F., et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp. Hematol. 34 (2006) 115-121
82. Sozzani S., et al. Linking stress, oxidation and the chemokine system. Eur. J. Immunol. 35 (2005) 3095-3098
83. van Muiswinkel F.L., and Kuiperij H.B. The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 267-281
84. Kappos L., et al. Efficacy of a novel single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: a phase 2 study. J. Neurol. 253 (2006) 27
85. Coles A.J., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46 (1999) 296-304
86. Lundin J., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
87. Coles A.J. Alemtuzumab compared with subcutaneous high-dose IFN-beta-1a in treatment naive relapsing-remitting multiple sclerosis: primary efficacy outcomes of CAMMS223 at 3 years. CAMMS Study Group. Neurology 70 Suppl. (2008) S22.006
88. Bielekova B., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8705-8708
89. Rose J.W., et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56 (2004) 864-867
90. Monson N.L., et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol. 62 (2005) 258-264
91. Rastetter W., et al. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med. 55 (2004) 477-503
92. Stuve O., et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62 (2005) 1620-1623
93. Eisenberg R., and Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2 (2006) 20-27
94. Cross A.H., et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180 (2006) 63-70
95. Cree B.A., et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 (2005) 1270-1272
96. Hauser S.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
97. Fujita T., et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo) 47 (1994) 208-215
98. Fujimoto T., et al. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J. Neuroimmunol. 95 (1999) 35-42
99. Kappos L., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355 (2006) 1124-1140
100. Loeb J.A. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 68 22 Suppl. 3 (2007) S38-S42
101. Lobell A., et al. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J. Immunol. 170 (2003) 1806-1813
102. Bar-Or A., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 64 (2007) 1407-1415
103. Barkhof F., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 Pt 11 (1997) 2059-2069
104. Tintore M., et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am. J. Neuroradiol. 21 (2000) 702-706
105. Andersson M., et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry 57 (1994) 897-902
106. Link H., and Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest. 37 (1977) 397-401
107. Freedman M.S., et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch. Neurol. 62 (2005) 865-870
108. Chiappa K.H. Use of evoked potentials for diagnosis of multiple sclerosis. Neurol. Clin. 6 (1988) 861-880